What Is Ipamorelin?

Raun et al. (Eur. J. Endocrinol.): First characterization showing Ipamorelin releases GH potently and selectively without raising ACTH, cortisol, prolactin, FSH, LH, or TSH in swine.

Dose-escalation study in healthy humans demonstrates Ipamorelin induces single-episode GH release with peak at ~0.67 hours and terminal half-life of 2 hours.

Svensson et al. show Ipamorelin induces dose-dependent longitudinal bone growth and counters glucocorticoid-induced decreases in bone formation and muscle strength.

Preclinical evidence demonstrates Ipamorelin alleviates delayed gastric emptying and post-surgical ileus, suggesting applications beyond hormone optimization.

A 2026 review found that nine therapeutic peptides, including tirzepatide, epitalon, and BPC-157, target diverse aging hallmarks such as metabolic dysfunction and tissue repair. While FDA-approved agents demonstrated robust safety, investigational peptides require further clinical validation to establish long-term efficacy.

A 2026 review found that many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, though rigorous human safety data remain scarce. The study investigated the pharmacological mechanisms and regulatory status of various sports medicine peptides.

A 2026 review found that performance-enhancing peptide use in sports and bodybuilding is increasing despite limited clinical evidence. The researchers demonstrated that these experimental substances carry poorly defined long-term risks, including potential cardiovascular strain and insulin resistance.

Therapeutic peptides, including BPC-157 and TB-500, were found to modulate molecular signaling networks influencing tissue regeneration and inflammation resolution in a 2026 review. The research highlighted their mechanistic potential for orthopaedic applications, noting a current lack of clinical trials.

Preclinical models demonstrate that peptides like BPC-157 and TB-500 show potential for tissue repair, but a 2026 review found a significant lack of human clinical data supporting their orthopaedic use.

A 2024 preclinical study found that the ghrelin mimetics anamorelin and ipamorelin inhibited cisplatin-induced weight loss in ferrets by approximately 24%. Additionally, centrally administered anamorelin demonstrated anti-emetic effects and improved food and water consumption during the acute phase.

A 2024 preclinical study demonstrated that the ghrelin agonist ipamorelin acetate significantly enhanced germ cell development and increased food intake in tilapia. Researchers found these effects were accompanied by elevated luteinizing hormone, 11-ketotestosterone, and androgen receptor expression.

A 2020 study found that the ghrelin mimetics ipamorelin and HM01 significantly attenuated non-inflammatory visceral hypersensitivity and somatic mechanical allodynia in rat models. The research demonstrated that peripherally restricted ghrelin receptor activation modulates pain responses in the absence of active inflammation.

Growth hormone secretagogues, including sermorelin, ibutamoren, and ipamorelin, demonstrated the ability to stimulate GH and IGF-1, potentially improving body composition in hypogonadal males. A 2020 review investigated these peptides, noting that while they may ameliorate fat gain, limited clinical data currently restricts their application.

A 2018 in vitro study found that a radiolabeled derivative of the peptidomimetic G-7039 exhibited high binding affinity and efficacy for the ghrelin receptor. Researchers successfully synthesized this compound, demonstrating its potential as a positron emission tomography imaging probe.

A 2018 study demonstrated that modifying ghrelin receptor ligands, including GHRP-6 and Ipamorelin, with a stable meta-carborane building block generated highly potent, boron-rich peptide agonists. These conjugates successfully activated the ghrelin receptor, indicating their potential utility as targeted delivery agents for boron neutron capture therapy research.

A 2019 study found that seized doping materials contained analogs of growth hormone secretagogues, including GHRP-2, GHRP-6, Ipamorelin, and modified GRF 1-29, modified with an extra N-terminal glycine amino acid. Researchers recommended updating analytical methods to target these specific peptide modifications.

A 2018 study identified a modified 192-amino acid human growth hormone and three novel peptide analogues—Gly-GHRP-6, Gly-GHRP-2, and Gly-Ipamorelin—in black market products. In-vitro experiments provided preliminary data on the potential metabolism of these extended peptides.

A 2017 study demonstrated that a novel spray-coated chemical stabilization mixture effectively prevented the enzymatic breakdown of small peptides, including GHRPs and ipamorelin, in urine samples. The findings support using these stabilized containers to prevent microbial and proteolytic degradation during doping control procedures.

A 2017 study demonstrated that specific amino acid modifications to the core structure of growth hormone-releasing peptides dictate their binding affinity to the GHSR1a receptor. Furthermore, researchers found that intact peptides and active metabolites remain detectable in urine following nasal administration.

A 2016 study demonstrated a highly sensitive method for detecting performance-enhancing peptides under 2 kDa, including GHRPs and TB-500, using direct urine injection and mass spectrometry. The assay successfully identified these compounds at concentrations between 50 and 500 pg/mL in human elimination samples.